SCHEMBL5453364

SCHEMBL5453364

NC(=O)c1c(NC(=O)Nc2cccnc2)sc2cc(O)ccc12

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.48
KMT2A Q03164 8/20 0.48
LMNA P02545 4/20 0.48
MAPT P10636 4/20 0.48
ALDH1A1 P00352 3/20 0.48
RAB9A P51151 5/20 0.46
NPC1 O15118 5/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TAAR1 Q96RJ0 1/20 0.44
HTT P42858 3/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.42
P2RX4 Q99571 1/20 0.42
GAA P10253 1/20 0.42
ATM Q13315 1/20 0.42
TSHR P16473 1/20 0.42
GRIK1 P39086 1/20 0.42
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459965 0.86 MDM2 (0.45) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL5451109 0.86 MEN1 (0.56) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL17625475 0.82 MEN1 (0.52) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL5453616 0.81 TRPV1 (0.51) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL5458283 0.80 MEN1 (0.43) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL5456326 0.80 MEN1 (0.43) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL5460182 0.79 MEN1 (0.50) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL5467416 0.79 TRPV1 (0.53) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL5455604 0.77 MAPT (0.48) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL17625474 0.77 CA12 (0.43) MEN1KMT2AMAPTALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MEN1 2891/4885KMT2A 4785/4885LMNA 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.